한글목차

PARP 억제제 세계 시장은 2025년에 78억 5,000만 달러, 2032년에는 143억 6,000만 달러에 달할 것으로 예측되며, 2025-2032년간 연평균 9.0% 성장할 것으로 예상됩니다.

그림.PARP 억제제 시장 점유율(%), 2025년 지역별 시장 점유율

폴리(ADP-리보오스) 중합효소(PARP) 억제제는 주로 암 치료에 사용되는 표적치료제의 일종입니다. 이들은 손상된 DNA를 복구하는 PARP 효소의 작용을 억제하여 화학요법이나 방사선 요법이 암세포를 보다 효과적으로 사멸시키는 데 도움을 줍니다. 세계 PARP 억제제 시장의 성장은 암 발병률 증가, 암 치료에서 PARP 억제제의 승인 및 채택 증가에 기인합니다. 이 시장의 주요 약물로는 유방암, 난소암, 전립선암 등의 치료에 효과가 입증된 올라파립, 닐라파립, 루카파립 등이 있습니다. 새로운 암종 및 병용요법에서 PARP 억제제의 가능성을 평가하기 위한 연구가 진행 중이기 때문에 이 시장은 성장할 가능성이 있습니다.

시장 역학

세계보건기구(WHO)에 따르면 2018년 암 환자 수는 1,810만 명, 사망자 수는 960만 명에 달하며, 암 발병률 증가와 암 분야에서의 PARP 억제제 승인 및 채택 확대가 PARP 억제제 세계 시장 성장의 원동력입니다. 보다 광범위한 환자군에서 PARP 억제제의 효능을 평가하기 위한 지속적인 임상시험과 다른 항암 치료와의 병용이 시장 성장을 가속할 수 있습니다. 그러나 PARP 억제제의 높은 가격, 환자 선택을 위한 유전자 사전 스크리닝의 필요성, 의약품 승인을 위한 엄격한 규제 경로의 부과는 시장 성장의 걸림돌이 될 수 있습니다. 새로운 용도를 찾기 위한 지속적인 연구와 새로운 파이프라인 의약품은 가까운 미래에 시장 성장에 새로운 기회를 제공할 수 있습니다.

본 조사의 주요 특징

• 세계의 PARP 억제제 시장을 상세하게 분석하여 2024년을 기준 연도로 하여 예측 기간(2025-2032년) 시장 규모(10억 달러)와 연평균 성장률(CAGR)을 조사 분석하여 전해드립니다.
• 또한, 다양한 부문에 걸친 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
• 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 중요한 고찰을 제공합니다.
• 이 보고서는 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과, 전략 등의 매개 변수를 기반으로 세계 PARP 억제제 시장의 주요 기업을 프로파일링합니다.
• 이 보고서의 통찰력을 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대, 마케팅 전술에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
• PARP 억제제 세계 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 이 산업의 다양한 이해관계자를 대상으로 합니다.
• 이해관계자들은 세계 PARP 억제제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.

목차

제1장 조사 목적과 전제조건

• 조사 목적
• 전제조건
• 약어

제2장 시장 전망

• 보고서 설명
  • 시장 정의와 범위
• 주요 요약
• Coherent Opportunity Map (COM)

제3장 시장 역학, 규제, 동향 분석

• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
• 영향 분석
• 시장 동향
• 규제 시나리오
• 인수와 제휴 시나리오
• 자금조달과 투자
• PEST 분석
• Porter의 Five Forces 분석

제4장 세계의 PARP 억제제 시장 - 코로나바이러스(COVID-19) 팬데믹의 영향

• 전체적인 영향
• 정부 이니셔티브
• 시장에 대한 COVID-19의 영향

제5장 세계의 PARP 억제제 시장, 약제 유형별, 2020-2032년(10억 달러)

• 서론
• Niraparib
• Olaparib
• Rucaparib
• Talazoparib
• Veliparib
• 기타

제6장 세계의 PARP 억제제 시장, 용도별, 2020-2032년(10억 달러)

• 서론
• 난소암
• 난관암
• 유방암
• 전립선암
• 췌장암
• 기타

제7장 세계의 PARP 억제제 시장, 유통 채널별, 2020-2032년(10억 달러)

• 서론
• 병원 약국
• 소매 약국
• 온라인 약국

제8장 세계의 PARP 억제제 시장, 지역별, 2020-2032년(10억 달러)

• 서론
• 북미
• 라틴아메리카
• 유럽
• 아시아태평양
• 중동
• 아프리카

제9장 경쟁 구도

• 기업 개요
  • AstraZeneca
  • GlaxoSmithKline
  • Merck Co. &Inc
  • AbbVie Inc
  • Clovis Oncology
  • Medivation
  • Johnson & Johnson Services, Inc
  • Pfizer Inc.
  • Genentech, Inc.
  • Artios Pharma
  • Repare Therapeutics Inc.
  • Sierra Oncology, Inc.
  • KaryopharmTherapeutics Inc.
  • Ono Pharmaceutical Co., Ltd.
  • Jiangsu Hengrui Medicine Co., Ltd.

제10장 애널리스트 추천 사항

• 융성과 쇠퇴
• Coherent Opportunity Map

제11장 참고 문헌과 조사 방법

• 참고 문헌
• 조사 방법

영문목차

Global PARP Inhibitor Market is estimated to be valued at USD 7.85 Bn in 2025 and is expected to reach USD 14.36 Bn by 2032, growing at a compound annual growth rate (CAGR) of 9.0% from 2025 to 2032.

Figure. PARP Inhibitor Market Share (%), By Region 2025

Poly (ADP-ribose) polymerase (PARP) inhibitors are a class of targeted therapies used mainly in cancer treatment. These work by blocking the action of PARP enzymes that repair damaged DNA, thus, helping chemotherapy and radiotherapy kill cancer cells more effectively. Global PARP inhibitor market growth is driven by rising cancer incidence, increasing approval and adoption of PARP inhibitors in oncology. Key drugs in the market include Olaparib, Niraparib and Rucaparib which have demonstrated efficacy in treating cancers like breast, ovarian and prostate. With ongoing research evaluating the potential of PARP inhibitors in newer cancer types and combination therapies, the can witness growth.

Market Dynamics:

Global PARP inhibitor market growth is primarily driven by increasing prevalence of cancer worldwide coupled with growing approval and adoption of PARP inhibitors in oncology. According to WHO, cancer burden has increased to 18.1 million new cases and 9.6 million deaths in 2018. Continuous clinical trials evaluating the efficacy of PARP inhibitors in broader patient segments and combination with other anti-cancer therapies can drive the market growth. However, high cost of PARP inhibitors, requirement of genetic pre-screening for patient selection and imposition of stringent regulatory pathways for drug approval can hamper the market growth. Ongoing research exploring newer applications and emerging pipeline drugs can offer new opportunities for market growth in the near future.

Key Features of the Study:

• This report provides in-depth analysis of the global PARP inhibitor market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global PARP inhibitor market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include AstraZeneca, Clovis Oncology, TESARO, AbbVie, Pfizer, Merck KGaA
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global PARP inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global PARP inhibitor market

Detailed Segmentation-

• By Drug Type
  • Niraparib
  • Olaparib
  • Rucaparib
  • Talazoparib
  • Veliparib
  • Others
• By Application
  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Breast Cancer
  • Prostate Cancer
  • Pancreatic Cancer
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • AstraZeneca
  • GlaxoSmithKline
  • Merck Co. & Inc
  • AbbVie Inc
  • Clovis Oncology
  • Medivation
  • Johnson & Johnson Services, Inc
  • Pfizer Inc.
  • Repare Therapeutics, Inc.
  • Genentech, Inc.
  • Artios Pharma
  • Sierra Oncology, Inc.
  • KaryopharmTherapeutics Inc.
  • Ono Pharmaceutical Co., Ltd.
  • Jiangsu Hengrui Medicine Co., Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Type
  • Market Snapshot, By Application
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global PARP Inhibitor Market- Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global PARP Inhibitor Market, By Drug Type, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Niraparib
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Olaparib
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Rucaparib
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Talazoparib
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Veliparib
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global PARP Inhibitor Market, By Application, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Ovarian Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Fallopian Tube Cancer
  • Mammography
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Breast Cancer
  • Chest X-ray
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Prostate Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Pancreatic Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global PARP Inhibitor Market, By Distribution Channel, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global PARP Inhibitor Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • AstraZeneca
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • GlaxoSmithKline
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Merck Co. & Inc
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • AbbVie Inc
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Clovis Oncology
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Medivation
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Johnson & Johnson Services, Inc
  • Pfizer Inc.
  • Genentech, Inc.
  • Artios Pharma
  • Repare Therapeutics Inc.
  • Sierra Oncology, Inc.
  • KaryopharmTherapeutics Inc.
  • Ono Pharmaceutical Co., Ltd.
  • Jiangsu Hengrui Medicine Co., Ltd.

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About Us and Sales Contact